Implementing Novel Agents in the Treatment of oHCM

Expert cardiologists share approaches to implementing mavacamten and aficamten in the clinical treatment of oHCM.

Related Keywords

Massachusetts ,United States ,Anjali Owens ,Andrew Wang ,Milind Desai ,James Januzzi ,Heart Center ,Risk Evaluation ,Mitigation Strategies ,Massachusetts General Heart Center ,Nt Pro Bnp ,Obstructive Hypertrophic Cardiomyopathy ,Johcm ,Left Ventricular Ejection Fraction ,Cp450 ,Atrial Fibrillation ,Drug Interactions ,Cardiac Myosin Inhibitors ,Long Term Efficacy ,Heart Failure ,Disease Modifying Therapies ,